Welcome to Elyvia Biomedics
Advancing Early Detection of Ovarian Cancer with an innovative molecular counter
The Challenge with Ovarian Cancer
High mortality rate
One out of two women diagnosed with ovarian cancer die within a relatively short period of time.
Patients exhibit vague symptoms, making the disease difficult to diagnose, and relapse rates remain high even after treatment.
Early detection is vital
Too often, ovarian cancer is detected too late, though survival rates are high when the disease is caught early. Today, only 20% of cases are caught at an early stage.
Surveillance is crucial for women at risk
Women with family history of ovarian cancer and breast cancer, or genetic mutation, are at risk of developing ovarian cancer.
Our Solution for Ovarian Cancer
A convenient blood test
Our proprietary technology enables an easy-to-use, device-agnostic blood test for point of care use, requiring only a small sample. We are developing a highly accurate, non-invasive device to catch ovarian cancer early.
A user-friendly digital experience
Our innovative solution combines classical biochemistry, a machine-learning powered digital system, and a visual intelligence app that can be integrated into healthcare settings.
Advancing precision therapy
Our approach enables longitudinal monitoring of a at-risk women and relapse patient, providing individualized ovarian cancer risk assessment over time.
About us
Founded in 2025, Elyvia Biomedics is an early-stage in-vitro diagnostics company dedicated to making early detection of ovarian cancer a reality.
To achieve this, we demonstrated a novel quantitative technology in proof-of-concept experiments and filed for a patent application with the European Patent Office.
Now, our team is committed to developing an innovative molecular counter device accompanied by a digital solution that enables early diagnosis and intervention, ultimately improving patient outcomes and saving lives.
Get in Touch
Please contact us via email at contact@elyvia.bio
